ABILIFY
LOE ApproachingNDAINTRAMUSCULARINJECTABLE
Approved
Sep 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
ABILIFY by Otsuka is unknown. First approved in 2006.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ABILIFY (aripiprazole) is an atypical antipsychotic injectable formulation approved in 2006 that works through partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors, combined with antagonist activity at 5-HT2A receptors. The intramuscular formulation (Maintena) is used for maintenance treatment of schizophrenia and bipolar disorder in patients who benefit from depot antipsychotics. It provides extended therapeutic coverage with reduced dosing frequency compared to oral formulations.
LOE Approaching
Product is in late-stage lifecycle with moderately elevated competitive pressure (30/100), signaling potential team restructuring and shift toward defensive strategies.
Mechanism of Action
unknown. The efficacy of aripiprazole could be mediated through a combination of partial agonist activity at dopamine D 2 and serotonin 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)
Started Apr 2021
535 enrolled
Bipolar Disorder I
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
Started Apr 2019
277 enrolled
Schizophrenia
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
Started Jun 2018
2 enrolled
SchizophreniaBipolar 1 DisorderMajor Depressive Disorder
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
Started Feb 2018
390 enrolled
Depression, Bipolar
Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition
Started Jun 2017
66 enrolled
Bioequivalence
Worked on ABILIFY at Otsuka? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.